Finanzen von MediciNova Inc (MNOV)MNOVMediciNova Inc

Evaluating the bottom line, MediciNova Inc maintains a gross margin of 69.31%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -554.31%, while the net margin is -504.79%. These profitability ratios, combined with a Return on Equity (ROE) of -25.56%, provide a clear picture of how effectively MNOV converts its operational activities into shareholder value.

In the context of the broader market, MNOV competes directly with industry leaders such as CTOR and ANVS. With a market capitalization of $64.48M, it holds a significant position in the sector. When comparing efficiency, MNOV's gross margin of 69.31% stands against CTOR's 67.07% and ANVS's N/A. Such benchmarking helps identify whether MediciNova Inc is trading at a premium or discount relative to its financial performance.

MediciNova has shown a remarkable increase in gross margin, reaching 69.31% in Q2 2026, compared to previous quarters where it was significantly lower. Despite this, the company continues to report negative net income, with a loss of -$2,314,139 in Q2 2026.